Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Meiji Licenses out ME3301 to Amalyte
June 15, 2009
- Vero Cell-derived Japanese Encephalitis Vaccine Released
June 15, 2009
- JCR Pharmaceuticals Expects Launching of EPO Biosimilar in April 2010
June 15, 2009
- OPINION／Why Empathy Is Key in Closing
June 15, 2009
- GSK, Pola to Copromote GSK's 4 Topical Agents
June 15, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 15, 2009
- Combined Operating Profits of 21 JPMA Members Plummet 13.7%
June 15, 2009
- Kyokaikenpo to Distribute Generics Request Card to Help Patients Request Generics
June 15, 2009
- BUSINESS NEWS IN BRIEF
June 15, 2009
- MEDICAL DEVICE NEWS IN BRIEF
June 15, 2009
- Tsumura: Record-High Profits Focusing on Kampo Medicines
June 15, 2009
- Takeda to Launch New Series of OTC Drugs for GI Disorders
June 15, 2009
- Industry Leaders Advocate Price Cut Exemption for Innovative Drugs at Chuikyo
June 15, 2009
- FPMAJ Proposes Replacement of Cost Calculation Method with a New One
June 15, 2009
- Opinions on the Review of the NHI Pricing Rule (Excerpt) Presented by the FPMAJ
June 15, 2009
- More Drugs Granted Premiums: Mr Nakagaki
June 15, 2009
- Sandoz's Somatropin to Be Approved as 1st Biosimilar Based on New Guidance
June 15, 2009
- Proposed Q&A for Guidance on Biosimilars Released
June 15, 2009
- MAA for Alogliptin in the EU to Be Delayed Until 2012: Takeda
June 15, 2009
- Asahi Kasei to Enhance Focus on Pharma Business
June 15, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…